Chimeric antigen receptors and CAR-T cells that bind CXCR5 and methods of use thereof to treat medical disorders

US11643468B2 · kind B2 · utility

Assignee

• Max-Delbrück-Centrum für Molekulare Medizin in der Helmholtz-Gemeinschaft · DE

Inventors

• Uta Höpken · Berlin, DE
• Armin Rehm · Berlin, DE
• Julia Bluhm · Berlin, DE
• Wolfgang Uckert · Berlin, DE

Key dates

• Filing date: Aug 23, 2018
• Grant date: May 9, 2023
• Expiry date: Dec 6, 2039

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C12N2510/00
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

An isolated chimeric antigen receptor polypeptide (CAR), wherein the CAR comprises an extracellular antigen-binding domain, comprising an antibody or antibody fragment that binds a human CXC chemokine receptor type 5 (CXCR5) protein. Also disclosed is a nucleic acid molecule encoding the CAR of the invention, a genetically modified immune cell, preferably a T cell, expressing the CAR of the invention and the use of said cell in the treatment of a medical disorder associated with the presence of pathogenic cells expressing CXCR5, preferably pathogenic mature B cells and/or memory B cells, and/or pathogenic T cells and/or T follicular helper cells, in particular mature B cell non-Hodgkin's lymphoma (B-NHL), T cell non-Hodgkin's lymphoma, or autoantibody-dependent autoimmune disease, preferably selected from systemic lupus erythematosus (SLE) or rheumatoid arthritis.